Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of angiotensin receptor 1 blocker versus calcium channel blocker on atherosclerotic plaque inflammation using serial FDG PET/CT imaging of carotid artery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CHEOL WHAN LEE, M.D., Ph.D
• Collaborator: Boryung Pharmaceutical Co., Ltd
• Treatments: Amlodipine; Ezetimibe, Simvastatin Drug Combination; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Men or Women at least 18 years of age inclusive

• Patients with acute coronary syndromes or unstable angina pectoris

• Hypertension or blood pressure more than 140/90mmHg

• FDG PET/CT shows at least 1 hot uptakes at carotid and or ascending aorta

• The patient or guardian agrees to the study protocol and the schedule of clinical and FDG PET/CT follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion Criteria:

• Patients treated with carotid endarterectomy or stent placement

• Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).

• Untreated hyperthyroidism, or hypothyroidism

• Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.

• Evidence of congestive heart failure, or left ventricular ejection fraction < 40%.

• Significant renal disease manifested by serum creatinine > 2.0mg/dL, or creatinine clearance of < 40 ml/min (by Cockcroft-Gault method).

• Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal).

• History of adult asthma manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s).

• Unwillingness or inability to comply with the procedures described in this protocol.

• Patient's pregnant or breast-feeding or child-bearing potential.

• Type I Diabetes